Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warby ParkerWRBY -0.19%68 14-Day RSI is 47.85 as of Aug. 11, 2026. GuruFocus rates WRBY with a GF Score™ of 68/100 and a GF Value™ of $21.61 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Warby Parker ranks better than 65.24% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-11), Warby Parker's 14-Day RSI is 47.85.
The industry rank for Warby Parker's 14-Day RSI or its related term are showing as below:
WRBY's 14-Day RSI is ranked better than 65.24% of 866
companies
in the Medical Devices & Instruments industry
Industry Median: 52.925
vs WRBY: 47.85
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Warby Parker 14-Day RSI Related Terms
WRBY vs XRAY, LMAT, PLSE: 14-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Warby Parker's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Warby Parker 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Warby Parker's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warby Parker (WRBY) has a 14-Day RSI of 47.85 as of Aug. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Warby Parker and its competitors. According to the industry distribution chart, Warby Parker ranks #301 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 34.8%.
Is Warby Parker's 14-Day RSI too high?
Warby Parker's current 14-Day RSI is 47.85. The Medical Devices & Instruments industry median 14-Day RSI is 52.93. Warby Parker's value of 47.85 is 9.6% below this industry median. Based on the distribution chart, Warby Parker ranks #301 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Warby Parker has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Warby Parker's 14-Day RSI compare to XRAY and LMAT?
According to the Medical Devices & Instruments industry distribution chart, Warby Parker ranks #301 out of 866 companies for 14-Day RSI. This puts Warby Parker in the upper half of its industry. The industry median 14-Day RSI is 52.93. Warby Parker's value of 47.85 is 9.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 52.93, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Warby Parker's current 14-Day RSI of 47.85 is 9.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Warby Parker and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 52.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Warby Parker's current 14-Day RSI is 47.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Warby Parker stock overvalued right now?
Based on GuruFocus' analysis, Warby Parker (WRBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.61, compared to a current price of $26.41 — trading 22.2% above its estimated fair value. The current 14-Day RSI is 47.85 and 9.6% below the Medical Devices & Instruments industry median of 52.93. Warby Parker's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Warby Parker (WRBY), the current 14-Day RSI is 47.85 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Warby Parker (WRBY) Overvalued in 2026?
Based on GuruFocus' analysis, Warby Parker stock appears to be overvalued.
The current stock price of $26.41 is trading 22.2% above its estimated GF Value™ of $21.61.
GuruFocus considers Warby Parker to be Modestly Overvalued.
Key valuation signals for WRBY:
14-Day RSI: 47.85
GF Value™: $21.61 vs. price of $26.41 (22.2% above fair value)
Industry Position: 9.6% below the Medical Devices & Instruments median (#301 of 866)
No single metric tells the full story. See the WRBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
68GF Score
Get the complete analysis for WRBY
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WRBY has been successfully added to your 
